^
Association details:
| Biomarker: | MET exon 14 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rybrevant (amivantamab-vmjw) (EGFR inhibitor, c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
......
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
......
More C2 evidence
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
......
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
......
Source:
Title:
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Excerpt:
......
Trial ID:
Source:
Title:
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Excerpt:
......
Trial ID:
Source:
Title:
A Clinical Study to Evaluate the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer Un estudio clínico para evaluar la seguridad y la eficacia de la terapia combinada de amivantamab y capmatinib en el cáncer de pulmón no microcítico metastásico irresecable
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
Published date:
08/08/2023
Excerpt:
In this larger patient population, amivantamab demonstrated antitumor activity in NSCLC patients with primary METex14, including those who failed MET inhibitors. Safety profile was consistent with the previously reported experience of amivantamab in EGFR-driven NSCLC.
Source:
Title:
Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.
Published date:
05/26/2022
Excerpt:
Overall response rate was 33% (50% [3/6] in treatment-naïve pts, 46% [5/11] in pts with no prior MET inhibitor, and 21% [4/19] in pts with prior MET inhibitor therapy). Clinical benefit rate was >54% regardless of prior treatment...Amivantamab demonstrates anti-tumor activity in primary METex14 NSCLC including after prior MET inhibitor treatment.
DOI:
10.1200/JCO.2022.40.16_suppl.9008
Trial ID:
Source:
Title:
Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Published date:
08/19/2021
Excerpt:
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [<80 kg] / 1400 mg [≥80 kg]).
Source:
Title:
OA15.03 - Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS
Published date:
08/18/2021
Excerpt:
...16 patients with METex14 NSCLC had received amivantamab at the RP2D....Nine patients had at least 1 postbaseline disease assessment, 7 are pending first disease assessment; 13 remain on treatment. Antitumor activity was observed in each of the 9 response-evaluable patients, with 4 confirmed partial responses, including patients with prior anti-MET therapy...This report provides first evidence of amivantamab activity in MET-driven NSCLC...
